Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report 2025 – For Visionary Product and Strategy Executives
Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the projected market size of the alpha-1 antitrypsin deficiency augmentation therapy industry, and what is its expected CAGR?
The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.
The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.
Download Your Free Sample PDF:
What external factors are influencing the alpha-1 antitrypsin deficiency augmentation therapy market’s growth momentum?
An increase in the number of respiratory diseases is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are disorders that affect the lungs and the respiratory system, leading to breathing difficulties and impaired lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to treat respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. The therapy works by restoring the balance of protease-antiprotease activity in the lungs, protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the increase in the number of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
class=reporthtag>Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Driver: Increase In The Number Of Clinical Trials Is Anticipated To Boost The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
The increase in the number of clinical trials is expected to propel the growth of the alpha-1 antitrypsin deficiency augmentation therapy market going forward. A clinical trial refers to a biomedical or behavioral research study conducted on human participants to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials are essential for the development and approval of new therapies and drugs for the treatment of AATD. The increase in the number of clinical trials indicates that there is a growing interest in the development of new therapies for AATD, which can lead to the introduction of new and more effective treatments in the market. For instance, in May 2023, according to a report published by Xtalks, a Canada-based web news and information network, there are 452,604 clinical studies that have been registered on ClinicalTrials.gov as of May 2023. This marks a significant rise from the more than 365,000 registered trials that were recorded in early 2021. Therefore, the increase in the number of clinical trials is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
What are the major market segments driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy industry?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
View The Full Market Report:
What are the key trends shaping the alpha-1 antitrypsin deficiency augmentation therapy market in the forecast period?
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative therapies, such as recombinant technology-based drug development, to sustain their position in the market. The recombinant DNA technology is used to manufacture therapeutic pharmaceuticals recombinant technology-based drug development. This method includes modifying the DNA of live organisms to synthesize specific proteins. For instance, in March 2022, Inhibrx Inc., a US-based biotechnology company, announced that INBRX-101 had received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein with the potential for a once-monthly dosage. It is intended to safely achieve and maintain levels of AAT found in healthy individuals.
Who are the key market players contributing to the growth of the alpha-1 antitrypsin deficiency augmentation therapy industry?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.
Which regions are leading the growth of the alpha-1 antitrypsin deficiency augmentation therapy market globally?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment